Literature DB >> 30889571

Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.

Lucio Vilar1,2, Clarice Freitas Vilar3, Ruy Lyra4, Maria da Conceição Freitas3.   

Abstract

An appropriate diagnostic evaluation is essential for the most appropriate treatment to be performed. Currently, macroprolactinemia is the third most frequent cause of nonphysiological hyperprolactinemia after drugs and prolactinomas. Up to 40% of macroprolactinemic patients may present with hypogonadism symptoms, infertility, and/or galactorrhea. Thus, the screening for macroprolactin is indicated not only for asymptomatic subjects but also for those without an obvious cause for their prolactin (PRL) elevation. Before submitting patients to macroprolactin screening and pituitary magnetic resonance imaging, one should rule out pregnancy, drug-induced hyperprolactinemia, primary hypothyroidism, and renal failure. The magnitude of PRL elevation can be useful in determining the etiology of hyperprolactinemia. PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia. However, they can also be found in subjects with macroprolactinemia, drug-induced hyper-prolactinemia or chronic renal failure. By contrast, most patients with NFPAs, drug-induced hyperprolactinemia, macroprolactinemia, or systemic diseases present with PRL levels <100 ng/mL. However, exceptions to these rules are not rare. Indeed, up to 25% of patients harboring a microprolactinoma or a cystic macroprolactinoma may also have PRL <100 ng/mL. Falsely low PRL levels may result from the so-called "hook effect," which should be considered in all cases of large (≥3 cm) pituitary adenomas associated with normal or mildly elevated PRL levels (≤250 ng/mL). The hook effect may be unmasked by repeating PRL measurement after a 1:100 serum sample dilution.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Hyperprolactinemia; Macroprolactinemia; Pitfalls; Prolactin

Mesh:

Year:  2019        PMID: 30889571     DOI: 10.1159/000499694

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  11 in total

1.  Prolactin immunoassay: does the high-dose hook effect still exist?

Authors:  Véronique Raverot; Pauline Perrin; Philippe Chanson; Emmanuel Jouanneau; Thierry Brue; Gérald Raverot
Journal:  Pituitary       Date:  2022-07-06       Impact factor: 3.599

2.  Hypeprolactinemia: still an insidious diagnosis.

Authors:  Ludovica Aliberti; Irene Gagliardi; Romolo M Dorizzi; Stefano Pizzicotti; Marta Bondanelli; Maria Chiara Zatelli; Maria Rosaria Ambrosio
Journal:  Endocrine       Date:  2020-09-19       Impact factor: 3.633

3.  Prolactin response to antipsychotics: An inpatient study.

Authors:  Liana Dehelean; Ana-Maria Romosan; Ion Papava; Cristina Ana Bredicean; Victor Dumitrascu; Sorin Ursoniu; Radu-Stefan Romosan
Journal:  PLoS One       Date:  2020-02-04       Impact factor: 3.240

4.  The utility of prolactin serial sampling and the best prolactin cut-offs associated with persistent hyperprolactinemia.

Authors:  Catarina Cidade-Rodrigues; Filipe M Cunha; Catarina Chaves; Margarida Silva-Vieira; André Silva; Susana Garrido; Mariana Martinho; Margarida Almeida
Journal:  Porto Biomed J       Date:  2021-04-13

5.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

Review 6.  Common Pitfalls in the Interpretation of Endocrine Tests.

Authors:  Jose C Alvarez-Payares; Jesus David Bello-Simanca; Edwin De Jesus De La Peña-Arrieta; Jose Emilio Agamez-Gomez; Jhon Edwar Garcia-Rueda; Amilkar Rodriguez-Arrieta; Luis Antonio Rodriguez-Arrieta
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

7.  Utility of Cannulated Prolactin to Exclude Stress Hyperprolactinemia in Patients with Persistent Mild Hyperprolactinemia.

Authors:  Raya Almazrouei; Shamaila Zaman; Florian Wernig; Karim Meeran
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-06-22

8.  Galactorrhea during antipsychotic treatment: results from AMSP, a drug surveillance program, between 1993 and 2015.

Authors:  C Glocker; R Grohmann; R Engel; J Seifert; S Bleich; S Stübner; S Toto; C Schüle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-25       Impact factor: 5.270

Review 9.  The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.

Authors:  Edouard G Mills; Lisa Yang; Morten F Nielsen; Moustapha Kassem; Waljit S Dhillo; Alexander N Comninos
Journal:  Endocr Rev       Date:  2021-11-16       Impact factor: 19.871

10.  Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.

Authors:  Liguang Wei; Xialin Wei
Journal:  Hormones (Athens)       Date:  2021-07-18       Impact factor: 2.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.